Published: January 15, 2019
Money often spent while companies had drugs ‘under review for public reimbursement’ through PBS
Major pharmaceutical companies injected more than $34m into patient advocacy groups in four years, often at the same time as they lobbied for related drugs to be listed on the pharmaceutical benefits scheme, new research suggests.
A study published by University of Sydney’s Charles Perkins Centre on Wednesday has for the first time mapped the links between big pharmaceutical players and consumer health groups in Australia.
Continue reading...from The Guardian http://bit.ly/2SSv8BM
via
0 Comments